Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
Portfolio Pulse from
Alnylam Pharmaceuticals announced its preliminary Q4 and full year 2024 global net product revenues for its key products and provided 2025 revenue guidance and pipeline goals.
January 12, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported preliminary 2024 revenue figures for its products and provided guidance for 2025, indicating strong commercial and clinical performance.
The announcement of preliminary 2024 revenues and 2025 guidance suggests strong performance and future growth potential, likely boosting investor confidence and positively impacting ALNY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100